Skip to main content

Table 3 Univariate and multivariate analysis of factors associated with liver dysfunction

From: Prognostic value of baseline interleukin 6 levels in liver decompensation and survival in HCC patients undergoing radioembolization

Parameter Univariate analysis Multivariate analysis
Model 1a Model 2b
HR (95% CI) p value HR (95% CI) p value HR(95% CI) p value
IL6 (> 6.53 pg/mL) 3.1 (1.4–6.6) 0.003 2.67 (1.21–5.94) 0.016 2.5 (1.1–5.4) 0.024
IL8 (> 60.8 pg/mL) 1.5 (0.75–3) 0.25     
Sex (Male vs. Female) 0.66 (0.2–2.2) 0.49     
Age (≥ 65 vs. < 65 years) 0.99 (0.5–2) 0.97     
ECOG (1 vs. 0) 0.84 (0.38–1.9) 0.68     
Cirrhosis (Yes vs. No) 2 (0.62–6.6) 0.25     
Hepatitis B Etiology (Yes vs. No) 1.3 (0.17–9.3) 0.82     
Hepatitis C Etiology (Yes vs. No) 1.9 (0.88–3.9) 0.1     
Alcohol Etiology (Yes vs. No) 1.1 (0.54–2.2) 0.82     
Previous TACE (Yes vs. No) 1.6 (0.73–3.3) 0.25     
PVI (Yes vs. No) 1.4 (0.68–2.9) 0.37     
Child–Pugh (B vs. A) 3.3 (0.98–11) 0.053     
BCLC (C vs. B) 1.1 (0.53–2.3) 0.78     
Albumin (< 36 g/L) 3.0 (1.4–6.3) 0.003 1.41 (0.61–3.23) 0.421
Total bilirubin (≥ 17 µmol/L) 4.4 (2.2–9)  < 0.001 3.73 (1.72–8.06)  < 0.001
AFP (≥ 400 vs < 400 ng/mL) 1.6 (0.73–3.4) 0.25     
Diffuse disease (≥ 10 lesions) 0.68 (0.34–1.3) 0.27     
Extrahepatic disease 1.1 (0.53–2.5) 0.74     
mALBI grade (2b and 3 vs. 1 and 2a) 3.9 (1.9–8.1)  < 0.001 3.1 (1.5–6.5) 0.003
  1. Bold type indicates statistical significance;
  2. IL, interleukin; ECOG, Eastern Cooperative Oncology Group; TACE, transarterial chemoembolization; PVI, Portal vein invasion; BCLC, Barcelona Clinic Liver Cancer; AFP, alfa fetoprotein; mALBI, modified albumin–bilirubin
  3. aModel 1 was identified using Cox regression with albumin and total bilirubin, excluding mALBI grade
  4. bModel 2 was identified using Cox regression with mALBI grade as a composite factor, excluding albumin and total bilirubin